Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

Delayed Quote. Delayed  - 07/29 10:00:00 pm
11.4 USD   -0.87%
07/27 VANDA PHARMACEU : reports 2Q loss
07/27 VANDA PHARMACEU : Reports Second Quarter 2016 Financial Results
07/12 VANDA PHARMACEU : to Announce Second Quarter 2016 Financial Results ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Vanda To Pay Eli Lilly Up To $100 Million In Drug Development Agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2012 | 01:50pm CEST

Vanda Pharmaceuticals Inc. (>> Vanda Pharmaceuticals Inc.) agreed to pay Eli Lilly Co. (LLY) up to $100 million for the exclusive right to develop a drug that has shown some promise as a treatment for alcohol addiction.

Under its deal with Lilly, the biopharmaceutical company will pay a $1 million initial license fee and take responsibility for all development costs of the VLY-686 drug.

Lilly is also eligible to receive additional payments based upon certain milestones and royalties on sales. These milestones include $4 million for milestones achieved prior to a new drug application and up to $95 million for future regulatory approval and sales milestones.

Vanda, which focuses on treatments for central nervous system disorders, noted that prior research of VLY-686 has focused on its potential as a novel therapeutic for individuals struggling with dependence on alcohol.

"The licensing of VLY-686 is an important milestone for Vanda, as we continue to realize our vision of developing treatments to address unmet medical needs," said Chief Executive Mihael H. Polymeropoulos.

Vanda in February reported it swung to a loss in the fourth quarter as increased expenses outweighed higher revenue for the period.

Shares closed Friday at $4.49 and were inactive in premarket trade. The stock has slumped 42% over the past year.

-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stocks mentioned in the article : Vanda Pharmaceuticals Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
07/28 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
07/27 VANDA PHARMACEUTICALS : reports 2Q loss
07/27 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
07/27 VANDA PHARMACEUTICALS : Reports Second Quarter 2016 Financial Results
07/12 VANDA PHARMACEUTICALS : to Announce Second Quarter 2016 Financial Results on Jul..
06/30 VANDA PHARMACEUTICALS : to Present at the JMP Securities Life Sciences Conferenc..
06/30 VANDA PHARMACEUTICALS : Why Investors Love These Biotech's Stocks? - ImmunoGen, ..
06/24 VANDA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement (form 8-..
06/20 VANDA PHARMACEUTICALS : to Present at the JMP Securities Life Sciences Conferenc..
06/16 VANDA PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders..
More news
Sector news : Bio Therapeutic Drugs
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/27 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2016 Results - ..
07/27 Vanda Pharmaceuticals beats by $0.24, revenue in-line
07/26 Notable earnings after Wednesday?s close
06/15 Vanda nabs three-year market exclusivity for Fanapt for maintenance treatment..
05/27 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Financials ($)
Sales 2016 145 M
EBIT 2016 -31,2 M
Net income 2016 -25,9 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 3,40x
Capi. / Sales 2017 2,98x
Capitalization 493 M
More Financials
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 17,3 $
Spread / Average Target 51%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Howard H. Pien Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..22.45%493
AMGEN, INC.5.98%129 232
GILEAD SCIENCES, INC.-21.46%105 840
CELGENE CORPORATION-6.32%86 960
REGENERON PHARMACEUTIC..-21.69%44 671
VERTEX PHARMACEUTICALS..-22.91%23 993
More Results